{"brief_title": "EVA: Evista Alendronate Comparison", "brief_summary": "The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures", "condition": "Osteoporosis", "intervention_type": "Drug", "intervention_name": "raloxifene HCI and alendronate Na", "criteria": "Inclusion Criteria - 50-80 years of age, inclusive - 2 years since last menses - Dx femoral neck osteoporosis - No vertebral fractures Exclusion Criteria - Poor candidate for study drugs - Hx of diseases affecting bone metabolism - Hx of breast/estrogen-dependent cancer - Current use of osteoporosis drug therapy - Hx/high risk of VTE", "gender": "Female", "minimum_age": "50 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "id": "NCT00035971.xml"}